Personnel

Biopharm company names Herbert Conrad board director, appoints scientific advisory board

Published in Cancer Weekly, February 7th, 2006

Sapphire Therapeutics, Inc., a private biopharmaceutical company focused on cancer and metabolic disorders, announced the addition of a new director and the appointment of a scientific advisory board (SAB).

These appointments, along with recent management hires and promotions, are part of a controlled growth strategy to support two drugs in clinical development, advance the company's preclinical pipeline and in-license additional drug candidates.

Herbert J. Conrad became the sixth director on the board of Sapphire Therapeutics in late 2005. He was U.S. president of Roche Pharmaceuticals, a company with which he was affiliated for 33 years in senior...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry